s-sociation among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
The objective of this study was to examine the degree to which conventional cardiovascular (CV) risk factor changes induced by once-weekly exenatide (EQW) might explain the placebo-controlled differences in CV outcomes observed in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
As we can see from the illustration, Exenatide Cardiovascular Risk has many fascinating aspects to explore.
Herein we present additional data on associated changes in body composition and circulating levels of biomarkers of cardiovascular risk after 1 year of treatment.
Such details provide a deeper understanding and appreciation for Exenatide Cardiovascular Risk.
The study included patients at any level of cardiovascular risk and targeted 70% with known CVD, including coronary ar-tery disease, ischemic cerebrovascular disease, or atherosclerotic peripheral arterial disease.1 The primary end point was the first occurrence of death from cardiovas-cular causes, nonfatal myocardial infarction, or ...
This particular example perfectly highlights why Exenatide Cardiovascular Risk is so captivating.
EXSCEL will assess whether exenatide once-weekly can reduce cardiovascular events in patients with T2DM with a broad range of cardiovascular risk. It will also provide long-term safety information on exenatide once-weekly in people with T2DM.
were; Cardiovascular risks, Cardiovascular complications, glycaemic control.rnAll the studies reviewed except 1 showed that the use of exenatide BID as a monotherapy or in...
The effect of exenatide, administered once weekly, on modi-fiable cardiovascular risk factors was modest. The disproportionate use in the placebo group of diabetes therapies known to...
